/PRNewswire/ Egret Therapeutics, a clinical-stage company focused on the treatment of neurological diseases, today announced the expansion of its Scientific.
/PRNewswire/ Egret Therapeutics, a clinical-stage company focused on the treatment of neurological diseases, today announced the expansion of its Scientific.
Press Release
Washington University School of Medicine in St. Louis.
Washington University School of Medicine in St. Louis and Barnes-Jewish Hospital have established the Brain Tumor Center, a multidisciplinary practice of physicians and scientists whose mission is to provide leading-edge, patient-centric care for brain tumor patients while also developing transformative basic, translational and clinical research to develop new therapies and improve patient outcomes.
Neurosurgeon and scientist Albert H. Kim, MD, PhD, has been appointed inaugural director of the center, which is based at Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital. He also is a professor of neurosurgery, of genetics, of neurology and of developmental biology.
Brain Tumor Center established at Siteman Cancer Center – Washington University School of Medicine in St. Louis wustl.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wustl.edu Daily Mail and Mail on Sunday newspapers.
In mice, antibody removes amyloid, improves vessel function without raising risk of brain bleeds
Amyloid deposits (blue) in mouse brain tissue and blood vessels are reduced after treatment with an antibody that targets the protein APOE (right), a minor component of amyloid deposits, compared to a placebo antibody (left). Amyloid deposits in the brain increase the risk of dementia and strokes. Researchers at Washington University School of Medicine in St. Louis have identified an antibody that clears amyloid deposits from the brain without raising the risk of brain bleeds. (Image: Monica Xiong)
February 17, 2021 SHARE
As people age, a normal brain protein known as amyloid beta often starts to collect into harmful amyloid plaques in the brain. Such plaques can be the first step on the path to Alzheimer’s dementia. When they form around blood vessels in the brain, a condition known as cerebral amyloid angiopathy, the plaques also raise the risk of strokes.